Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer

NCT07813637 is registered in ClinicalTrials.gov with Janux Therapeutics as lead sponsor.

NCT NCT07813637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07813637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Janux Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 10, 2026
Completion date
July 31, 2030
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer (crpc), metastatic castration-resistant prostate cancer patients, metastatic prostate cancer, prostate cancer